Results 141 to 150 of about 11,226 (207)

Management of relapsed/refractory AL amyloidosis. [PDF]

Blood Adv
Ling J, Sidiqi MH, Gertz M.
europepmc   +1 more source

Anti-CD38 Therapy With Daratumumab in High-Risk IgA Nephropathy. [PDF]

Kidney Int Rep
Poux M, De Vriese AS, Cohen C, Duong Van Huyen JP, Daugas E, Jolivot A, Joher N, Matignon M, Hertig A, El Karoui K.   +9 more
europepmc   +1 more source

Plenary Abstracts Session & Oral Presentations

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Refractory severe type B insulin resistance treated with daratumumab. [PDF]

JCEM Case Rep
Munugoti S, Gaddam M, Rasool N, Shevtsov P, Piranavan P, Kern PA.   +5 more
europepmc   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Front-line treatment approaches in multiple myeloma: real-world data from a community-based oncology network. [PDF]

Front Oncol
Paulson RS, Gautam S, Medhekar R, Mahmud S, Mirsalehi A, Ensley L, Shelley B, Brisbin L, Lisi M, Khare V, Kaila S, Levy MY.   +11 more
europepmc   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Smoldering Multiple Myeloma: Early Intervention or Structured Surveillance? A Comprehensive Review of Evidence for and Against Early Therapy. [PDF]

Cancers (Basel)
Arora K, Soueid L, Williams L, Grover J, Basali D, Khouri J, Kaushal Y, Mazzoni S, Dahiya R, Faiman B, Valent J, Anwer F, Raza S.   +12 more
europepmc   +1 more source

Daratumumab in relapse-refractory immune-mediated thrombotic thrombocytopenic purpura: additional evidence for its efficacy. [PDF]

Res Pract Thromb Haemost
Coppo P.
europepmc   +1 more source

Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial. [PDF]

EClinicalMedicine
Chen Y, Hua Z, Xu Y, Chen J, Wen Q, Sun T, Li H, Liu X, Fu R, Ju M, Xue F, Liu W, Dong H, Gu W, Dai X, Wang W, Chi Y, Pei X, Yang R, Zhang L.   +19 more
europepmc   +1 more source